Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-3 belantamab mafodotin versus pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
2018-004252-38Phase 3Unknown
- Sponsor
- GSK
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Belantamab mafodotin monotherapy with Pomalidomide + low-dose dexamethasone (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
belantamab mafodotinpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-004252-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004252-38.